PVX-410 + pembrolizumab + chemotherapy

PVX-410 + pembrolizumab + chemotherapy is a combination investigational regimen studied primarily for metastatic, PD-L1-positive, HLA-A2-positive triple-negative breast cancer (TNBC). **PVX-410** is a multipeptide cancer vaccine targeting multiple antigens (X-box binding protein 1, syndecan-1/CD138, and CS1/SLAMF7) designed to stimulate a T cell-mediated immune response against tumor cells[2][4][8]. **Pembrolizumab** is a monoclonal antibody targeting the programmed death 1 (PD-1) receptor and acts as an immune checkpoint inhibitor, blocking the interaction between PD-1 and its ligands PD-L1/PD-L2 to promote antitumor immune responses[3][5][7]. **Chemotherapy** in these regimens typically refers to standard cytotoxic agents used in TNBC (e.g., paclitaxel, carboplatin), promoting direct cell death and immunomodulatory effects. The combination leverages vaccine-driven antigen-specific immunity, checkpoint blockade, and direct cytotoxicity in an attempt to enhance efficacy in TNBC. This drug regimen is under investigation and not approved for any indication[3]. Primary developer for PVX-410 is OncoPep; pembrolizumab is developed and manufactured by Merck & Co.[3][4].

Other names

PVX-410 vaccinePVX410 vaccinePVX 410 vaccinePD-1 inhibitor plus chemotherapyPD1 inhibitor plus chemotherapyPD 1 inhibitor plus chemotherapyPVX-410 vaccine plus pembrolizumab and chemotherapyPVX410 vaccine plus pembrolizumab and chemotherapyPVX 410 vaccine plus pembrolizumab and chemotherapy